INSIGHTS ON DRUG DEVELOPMENT

• New Approach Methodologies: The Future Of Toxicology And Safety Testing

  NAMs are transforming toxicology with human-relevant, non-animal approaches. Learn what defines a NAM, how these methods work together, and why adoption is rapidly accelerating.

• Dosage Form Scale-Up: Balancing Speed And Efficiency In Later-Stage Development

  Reduce development risk and improve readiness for larger trials with strategies that align formulation, manufacturing, and commercialization goals.

• Managing Process Knowledge Throughout Drug Development And Manufacturing

  Discover how digitalizing recipe and risk management helps life sciences teams accelerate drug development, streamline technology transfers, and simplify compliance to improve data integrity.

• Enhanced Validation Data Anti-EGFRvIII Recombinant Antibody

  Select the right antibody clone by exploring enhanced validation data for top recombinant antibody clones that offer comprehensive specificity and sensitivity insights tailored to your project's unique requirements.

• Embedded AI Is The Future Of Biopharmaceutical Recipe Creation

  4/28/2026

  AI-assisted recipe creation works differently across MES and DCS environments. Where the AI sits in the automation architecture, embedded or added on, shapes how well it handles GMP-scale complexity.

• Closing The QC Gap For mAbs: Rapid Answers Without Compromising

  6/9/2026

  Monoclonal antibodies are complex biologics requiring precise analytical strategies to monitor critical quality attributes and impurities, with molecular assays like qPCR supporting sensitive detection, product integrity, and regulatory compliance.

• Aggregation In Antibody-Drug Conjugates: Causes And Mitigation

  9/1/2025

  Discover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.

• Developing A Quantitative Surrogate Peptide Assay

  7/17/2025

  Discover a streamlined LC-MS/MS workflow for Fc-containing therapeutics like dulaglutide to enable precise quantification with LLOQ as low as 1 ng/mL through automated, efficient assay development.

• Practical Formulation Strategies For Poorly Soluble APIs

  10/2/2026

  Poor aqueous solubility now defines most drug candidates in development, making early screening and solid-state assessment essential to achieving reliable exposure and avoiding costly reformulation downstream.